Sumitomo Dainippon Pharma Co Ltd (JP:4506)
:4506
Want to see JP:4506 full AI Analyst Report?
4506 Stock Chart & Stats
¥1854.50
¥4.00(0.72%)
At close: 4:00 PM EST
¥1854.50
¥4.00(0.72%)
Day’s Range― - ―
52-Week Range¥615.00 - ¥3,288.00
Previous CloseN/A
Volume1.08M
Average Volume (3M)5.45M
Market Cap
¥823.59B
Enterprise Value¥993.83B
Total Cash (Recent Filing)¥57.32B
Total Debt (Recent Filing)¥258.95B
Price to Earnings (P/E)26.1
Beta1.24
Next Earnings
May 19, 2026EPS Estimate
-15.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)22.19
Shares Outstanding397,900,150
10 Day Avg. Volume5,265,230
30 Day Avg. Volume5,454,233
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.71
Price to Sales (P/S)0.73
P/FCF Ratio36.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)224.64
Revenue Forecast (FY)¥514.21B
Bulls Say, Bears Say
Bulls Say
Strong TTM MarginsSustained high TTM net and EBIT margins point to durable pricing power and operational efficiency in core therapeutic areas. These margins support internal R&D funding and cushion near-term profitability against cyclical revenue swings, improving medium-term financial resilience.
Positive Free Cash FlowA high FCF level and strong conversion (FCF ≈ 0.88x net income) provide durable internal funding for drug development, debt reduction, and strategic investments. Over 2–6 months this reduces dependency on external financing and supports sustained capital allocation flexibility.
Improved LeverageLower debt-to-equity in the TTM period materially reduces financial risk and interest burden, increasing strategic optionality for R&D or M&A. Improved leverage is a structural stability factor that strengthens the balance sheet over the medium term.
Bears Say
Historic Earnings And Revenue VolatilityLarge prior losses and pronounced revenue swings indicate an unstable earnings base. This undermines cash-flow predictability, complicates long-range planning for pipeline investment and raises the company’s operational and financing risk over the coming months.
Weak Operating Cash ConversionOperating cash flow at ~0.25x of reported earnings signals earnings quality and working-capital issues. Persistent low cash conversion can constrain day-to-day liquidity, force reliance on non-operational cash or debt, and limit consistent funding for R&D or launches.
Balance-sheet Volatility Despite ImprovementSignificant swings in equity and historically high leverage create restart risk: a future downturn could rapidly re-elevate leverage or trigger covenant stress. This structural volatility raises the cost of capital and constrains strategic moves like acquisitions or sustained capex.
Sumitomo Dainippon Pharma Co News
4506 FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was ¥615.00 and its highest was ¥3288.00 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is ¥823.59B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is May 19, 2026 which is in 27 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on Jan 30, 2026. The company reported ¥22.19 earnings per share for the quarter, beating the consensus estimate of -¥0.87 by ¥23.06.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Overvalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd pays a Semiannually dividend of ¥7 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate is -15.24.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 397,900,150 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of ¥22.19 in its last earnings report, beating expectations of -¥0.87. Following the earnings report the stock price went up 5.343%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in JP:4506
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
4506 Company Deck
4506 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.View all JP:4506 earnings summariesTechnical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---